Astellas enters into definitive agreement to acquire Audentes Therapeutics
Astellas has announced that it will be acquiring Audentes Therapeutics at a total cost of $3 billion.
List view / Grid view
News
NICE approves new tablet formulation for olaparib drug
The UK NICE has extended its approval for olaparib, updating its formulation from eight capsules twice a day to two tablets twice daily.
High levels of pharmaceutical pollution found in industrialising counties
A study has revealed that in industrialising and urbanising countries, pharmaceutical pollution in rivers could lead to antimicrobial resistance.
Strategies developed for improving drug delivery for brain tumour treatment
Scientists have proposed combining ultrasound with other techniques to improve drug transport into brain tumours.
Medicinal cannabis product granted approval in Ireland
A medicinal CBD oil has been approved for importation, prescription and supply under the Medical Cannabis Access Programme (MCAP) in Ireland.
FDA updates guidance for adaptive clinical trial reporting
The US Food and Drug Administration has announced new guidance for drug applications that include results from adaptive clinical trials.
Dr Richard Torbett named as new ABPI Chief Executive
The ABPI’s board has unanimously appointed Dr Richard Torbett as Chief Executive, commencing 1 January 2020.
Priority Review granted to pemigatinib for treatment of cholangiocarcinoma
The US FDA has awarded pemigatinib Priority Review, after the drug met its primary and secondary endpoints in a Phase II trial.
Campaign calls for more effort to combat counterfeit medicines
A week-long awareness-raising campaign has been launched to combat the spread of substandard and falsified medicines.
NICE approves breast cancer treatment through Cancer Drugs Fund
NICE has approved palbociclib through the Cancer Drugs Fund, meaning that women with advanced breast cancer who have already received hormone therapy will now be eligible for palbociclib on the NHS.
Drug prices in China cut by up to 61 percent for reimbursement scheme list
Top pharmaceutical companies have reduced their drug costs in China by an average of 61 percent, to be added to the reimbursement list in the country.
Political parties focus on R&D and mental health ahead of UK election
The three largest UK political parties have published their manifestos for the upcoming election which focus on various pharma initiatives including the NHS, R&D, drug prices and mental health.
The FDA has approved Exservan™ for the treatment of ALS
The FDA has granted early-action approval to Exservan for the treatment of ALS, which can be administered safely and easily without water.
Generics and biosimilars vital to reduce healthcare costs, finds EC
The EC has released a report that has found generics and biosimilars decrease wasteful spending and maintain health quality in the EU.
FDA issues warning letter for marketing unapproved products
A warning letter has been issued by the FDA for products illegally marketed for the treatment of health conditions, including opioid withdrawal symptoms.
